Starpharma Holdings Limited (DE:PQ6)
FRANKFURT:PQ6
PQ6 Stock Chart & Stats
€0.20
<€0.01(5.36%)
At close: 4:00 PM EST
€0.20
<€0.01(5.36%)
Day’s Range― - ―
52-Week Range€0.03 - €0.47
Previous CloseN/A
Volume0.00
Average Volume (3M)873.00
Market Cap
€174.28M
Enterprise Value€277.19M
Total Cash (Recent Filing)€18.25M
Total Debt (Recent Filing)€790.00K
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding420,928,440
10 Day Avg. Volume390
30 Day Avg. Volume873
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)1.93
Price to Sales (P/S)7.47
P/FCF Ratio-5.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Dendrimer Platform & Licensing ModelStarpharma's proprietary dendrimer platform and licensing/collaboration revenue model create durable, scalable revenue streams. Partner-funded development, milestone and royalty structures reduce the firm’s need to self-fund all clinical risk, supporting commercialization without sole reliance on internal product sales.
Conservative Leverage And Solid Capital StructureLow debt and a healthy equity ratio give Starpharma long-term financial flexibility to fund R&D and absorb biotech volatility. Conservative leverage reduces refinancing and interest risks, enabling the company to pursue collaborations or selective investment without immediate pressure to generate positive operating cash flow.
Positive Revenue Growth With Solid Gross MarginSustained revenue growth alongside relatively strong gross margins indicates product or licensing uptake and underlying commercial traction. This top-line momentum provides a foundation to improve operating leverage over time if management controls SG&A and R&D, supporting a path to eventual profitability.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow reduces the company’s ability to self-fund development and commercialization, increasing reliance on external financing or partner deals. Over months this limits strategic optionality and can lead to dilution or delayed programs if cash generation doesn't improve.
Persistent Negative EBIT And Net MarginsOngoing negative EBIT and net margins point to structural operating inefficiencies or heavy investment stages. Until operating margins turn positive, the company cannot sustainably fund growth internally, which constrains reinvestment, weakens returns, and heightens dependency on partners or capital markets.
Negative Return On Equity Despite Healthy Equity BaseA negative ROE shows shareholder capital is not producing returns, raising concerns about capital allocation and long-term investor value creation. Even with a healthy equity ratio, persistent negative ROE can pressure future funding terms and limit the firm's ability to attract equity at favorable conditions.
Starpharma Holdings Limited News
PQ6 FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest stock price was €0.03 and its highest was €0.47 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is €174.28M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 73 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported €0.002 earnings per share for the quarter, beating the consensus estimate of N/A by €0.002.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 420,928,440 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of €0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in DE:PQ6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.55%
12-Months-Change
Fundamentals
Return on Equity
-15.96%
Trailing 12-Months
Asset Growth
-4.84%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---